(0.30%) 5 115.19 points
(0.30%) 38 355 points
(0.34%) 15 982 points
(-0.92%) $83.08
(5.77%) $2.03
(0.36%) $2 355.70
(0.44%) $27.66
(4.02%) $959.15
(-0.22%) $0.933
(-0.38%) $10.98
(-0.54%) $0.796
(1.69%) $93.43
Live Chart Being Loaded With Signals
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions...
Stats | |
---|---|
本日の出来高 | 61 900.00 |
平均出来高 | 146 095 |
時価総額 | 2.20M |
EPS | $0 ( 2024-02-20 ) |
次の収益日 | ( $-0.360 ) 2024-05-09 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.120 |
ATR14 | $0.00600 (1.81%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-04 | Mento Steven J | Buy | 10 000 | Stock Option (Right to Buy) |
2024-01-04 | Proehl Gerald T | Buy | 125 000 | Stock Option (right to buy) |
2024-01-04 | Fisher Mary | Buy | 10 000 | Stock Option (Right to Buy) |
2024-01-04 | Scott Kathleen D. | Buy | 10 000 | Stock Option (Right to Buy) |
2024-01-04 | Sandler Andrew Seth | Buy | 10 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
100.00 |
Last 98 transactions |
Buy: 8 169 572 | Sell: 872 238 |
Dermata Therapeutics, 相関
10 最も正の相関 | |
---|---|
SVAC | 0.964 |
PAIC | 0.955 |
TLGT | 0.926 |
SVOK | 0.917 |
RMRM | 0.917 |
SPRT | 0.885 |
EARS | 0.875 |
PROG | 0.873 |
BLPH | 0.863 |
FORE | 0.859 |
10 最も負の相関 | |
---|---|
NETE | -0.977 |
AMRB | -0.924 |
MMAC | -0.903 |
RAVN | -0.892 |
SRAC | -0.88 |
ANIK | -0.866 |
BOCH | -0.85 |
ATHN | -0.849 |
CPTN | -0.839 |
ODT | -0.835 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Dermata Therapeutics, 財務諸表
Annual | 2023 |
収益: | $0 |
総利益: | $0 (0.00 %) |
EPS: | $-2.67 |
FY | 2023 |
収益: | $0 |
総利益: | $0 (0.00 %) |
EPS: | $-2.67 |
FY | 2022 |
収益: | $0 |
総利益: | $0 (0.00 %) |
EPS: | $-13.92 |
FY | 2021 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-2.43 |
Financial Reports:
No articles found.
Dermata Therapeutics,
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions. The company was incorporated in 2014 and is headquartered in San Diego, California.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。